Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03307174 · ClinicalTrials.gov registry record · Phase 4

Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.

A Phase 4 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 4
Development phase
120
Enrollment target

NCT03307174 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 120 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03307174, a Phase 4 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 4
Development phase
120 participants
Enrollment target

Study Summary

Epidurals are an effective means for providing neuraxial anesthesia and analgesia. Prior studies in labor epidurals have demonstrated that a programmed intermittent bolus application of local anesthesia can improve pain control by reducing the amount of local anesthetic required as well as improve patient satisfaction when compared to continuous epidural infusions. The effects of programmed intermittent bolus of epidural local anesthetics compared to continuous epidural infusions in a surgical setting have yet to be elucidated. Our goal is to evaluate the use of programmed intermittent bolus compared to continuous epidural infusion in a surgical patient population. We plan to enroll patients already undergoing abdominal surgeries including colorectal, gynecologic, surgical oncology, urological where epidural anesthesia can be employed. The primary endpoints of the study will be the total local anesthetic consumption and total opioid consumption as surrogate markers for the quality of epidural anesthesia. Secondary endpoints are pain scores and functional measurements, patient satisfaction, and incidence of hypotension.

Interventions

  • DRUG Bupivacaine
  • DRUG Fentanyl

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2016-04-14
Est. Completion 2019-02-28
Phase Phase 4

What the Registry Record Tells You About NCT03307174

The ClinicalTrials.gov registry entry for NCT03307174 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.

NCT03307174 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03307174 about?

NCT03307174 is a clinical study titled "Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.". Epidurals are an effective means for providing neuraxial anesthesia and analgesia. Prior studies in labor epidurals have demonstrated that a programmed intermittent bolus application of local anesthesia can improve pain control by reducing the amount of local anesthetic required as well as improve p...

What is the current status of trial NCT03307174?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2016-04-14. Estimated completion is 2019-02-28.

What interventions are being tested in trial NCT03307174?

The interventions under investigation include: Bupivacaine (DRUG), Fentanyl (DRUG).

Who is sponsoring clinical trial NCT03307174?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.